Search
for
Sort by
Research 61–90 of 1000+
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
- Impacto del desequilibrio del microbioma del cuero cabelludo en la severidad de la alopecia areata, marcadores inflamatorios y cambios post-tratamiento
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Continued treatment with baricitinib results in meaningful scalp responses among scalp non‐responder patients with eyebrow/eyelash regrowth in the first year
- Gut microbiome, metabolome and alopecia areata
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Upadacitinib Therapy in Adolescent Severe Alopecia Areata: A Case Series and Narrative Review
- Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
- Significant efficacy of tofacitinib from China in the treatment of alopecia areata: a case report
- Baricitinib maintains regrowth of hair, eyebrows, and eyelashes over 3 years
- Efficacy and Safety of Baricitinib in Patients With Alopecia Areata: A Real‐World Cohort Study
- Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
- Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Exploring novel management options for alopecia areata
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- MODERN BIOLOGICAL TREATMENT METHODS FOR ALOPECIA AREATA: A COMPREHENSIVE REVIEW
- The first 20 years of skin of color dermatology: An era of advancements in skin, hair, and nail disorders
- Spotlight in Plastic Surgery: October 2022
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
- SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study